Blog
RSS FeedPosted by Michael Wonder on 06 Jan 2017
German IQWiG confirms additional benefit for Kisplyx (lenvatinib mesylate) in combination with everolimus for the treatment of advanced renal cell carcinoma
4 January 2017 - Approximately 15,000 people in Germany develop renal cell carcinoma every year. ...
Posted by Michael Wonder on 06 Dec 2016
Considerable additional benefit of Eisai's Halaven (eribulin mesylate) in advanced liposarcoma confirmed by the German Federal Joint Committee
4 December 2016 - Eribulin mesylate has shown unprecedented survival benefit in advanced liposarcoma in pivotal phase III trial. ...
Posted by Michael Wonder on 16 Nov 2016
Pembrolizumab in lung cancer: evidence of considerable additional benefit
16 November 2016 - Significant advantages when compared to docetaxel. ...
Posted by Michael Wonder on 16 Nov 2016
Trifluridine-tipiracil combination in colorectal cancer: additional benefit only for some patients
16 November 2016 - Low benefit for patients with K-RAS wild type; survival benefits, but significant side effects and missing ...
Posted by Michael Wonder on 17 Oct 2016
Sofosbuvir with velpatasvir in chronic hepatitis C: hint of added benefit in two of ten subindications
17 October 2016 - Historical comparisons and considerations of individual study arms unsuitable for conclusions on the other research questions. ...
Posted by Michael Wonder on 17 Oct 2016
Emtricitabine/rilpivirine/tenofovir alafenamide in HIV: added benefit not proven
17 October 2016 - Research questions on adolescents not investigated/evidence on components not simply transferable to the combination. ...
Posted by Michael Wonder on 05 Oct 2016
Sitagliptin and sitagliptin with metformin hydrochloride in type 2 diabetes mellitus: additional benefit compared to sulphonylurea plus metformin hydrochloride
4 October 2016 - For other questions, an additional benefit has not been established. ...
Posted by Michael Wonder on 05 Oct 2016
Saxagliptin and saxagliptin with metformin hydrochloride in type 2 diabetes mellitus: additional clinical benefits still not there
4 October 2016 - Study evaluations unsuitable for statements about the positive or negative effects over comparative therapies. ...
Posted by Michael Wonder on 04 Oct 2016
Crizotinib in NSCLC: new data are inconclusive
4 October 2016 - Increased proportion of treatment-change limits further interpretability so the results of the initial IQWiG evaluation shall continue. ...
Posted by Michael Wonder on 04 Oct 2016
Ibrutinib in CLL: no additional clinical benefits for treatment-naïve patients
4 October 2016 - The dossier contains no suitable data on first-line use. ...
Posted by Michael Wonder on 26 Sep 2016
Nivolumab plus ipilimumab in melanoma: added benefit in certain patients
15 September 2016 - Survival advantage in BRAF V600 wild type tumour depends on gender / severe side effects more common. ...
Posted by Michael Wonder on 19 Sep 2016
Talimogene laherparepvec in melanoma: additional clinical benefit not proven
15 September 2016 - Drug manufacturer dossier contained no data suitable for the assessment. ...
Posted by Michael Wonder on 17 Sep 2016
Selexipag in pulmonary arterial hypertension: additional clinical benefit is not proven
16 September 2016 - Limited comparator therapy and division of population inadequate/the only study compared the medicine with placebo. ...
Posted by Michael Wonder on 15 Sep 2016
Ticagrelor for prevention after myocardial infarction: added benefit called into question by data subsequently submitted
15 September 2016 - Greater consistency and certainty of conclusions of the results regarding harmful aspects. ...
Posted by Michael Wonder on 07 Sep 2016
Eribulin in liposarcoma: added benefit not proven
1 September 2016 - Neither results from a study of direct comparison nor from an indirect comparison were suitable. ...